首页 > 最新文献

Journal of Evidence‐Based Medicine最新文献

英文 中文
Topical antimitotic treatments for plantar warts are more beneficial: A Bayesian network meta-analysis of randomized controlled trials 跖疣的局部抗炎治疗更有益:随机对照试验的贝叶斯网络荟萃分析。
IF 7.3 2区 医学 Q1 Medicine Pub Date : 2024-01-19 DOI: 10.1111/jebm.12586
Yantao Xu, Ying Wang, Kai Huang, Weihong Huang, Shuang Zhao, Zixi Jiang

Background

Plantar warts are common infectious cutaneous growths causing severe physiological and psychological discomforts in patients and heaving global financial burdens. However, paucity of clear-cut guidelines for plantar warts, selecting appropriate treatments for plantar warts remains challenging. The objective of the study is to evaluate the efficacy and safety of common treatments for plantar warts.

Methods

PubMed, EMbase, and The Cochrane Library were searched from inception to March 1, 2023 for randomized controlled trials (RCTs) of plantar warts. The primary outcome (complete response) and secondary outcome (recurrence and pain) were extracted and combined using Bayesian network meta-analysis (NMA) with random-effect and fixed-effect models.

Results

Totally, 33 RCTs were included in the systematic review and quantitative NMA. In NMA of complete response, topical application of 1% cantharidin, 20% podophylotoxin, 30% salicylic acid (CPS), microneedles plus bleomycin (MNB), and intralesional bleomycin injection (INB) were the only three treatments significantly superior to no treatment (NT) and CPS was of the highest possibility to be the top-ranked treatment (SUCRA = 0.9363). However, traditional warts treatments, salicylic acid (SA) and cryotherapy were not superior to NT.

Conclusions

The NMA has produced evidence for using CPS, MNB, and INB, which are all topical antimitotic treatments, to improve the management of plantar warts. The classic treatment modalities for plantar warts, including SA and cryotherapy, may play a less important role in the clinical practice of plantar warts.

背景:跖疣是一种常见的传染性皮肤赘生物,会给患者造成严重的生理和心理不适,并给全球带来沉重的经济负担。然而,由于缺乏明确的跖疣治疗指南,选择适当的跖疣治疗方法仍具有挑战性。本研究旨在评估跖疣常见治疗方法的有效性和安全性:方法:在 PubMed、EMbase 和 Cochrane 图书馆检索了从开始到 2023 年 3 月 1 日的跖疣随机对照试验 (RCT)。采用贝叶斯网络荟萃分析(NMA)和随机效应与固定效应模型提取并合并了主要结果(完全应答)和次要结果(复发和疼痛):共有 33 项研究纳入了系统综述和定量 NMA。在完全反应的NMA中,局部应用1%卡他列汀、20%荚膜霉素、30%水杨酸(CPS)、微针加博莱霉素(MNB)和局部注射博莱霉素(INB)是仅有的三种显著优于无治疗(NT)的治疗方法,而CPS最有可能成为排名第一的治疗方法(SUCRA = 0.9363)。然而,传统的尖锐湿疣治疗方法、水杨酸(SA)和冷冻疗法并不优于NT:NMA为使用CPS、MNB和INB(均为局部抗炎治疗)改善跖疣治疗提供了证据。跖疣的传统治疗方法,包括SA和冷冻疗法,在跖疣的临床实践中发挥的作用可能较小。
{"title":"Topical antimitotic treatments for plantar warts are more beneficial: A Bayesian network meta-analysis of randomized controlled trials","authors":"Yantao Xu,&nbsp;Ying Wang,&nbsp;Kai Huang,&nbsp;Weihong Huang,&nbsp;Shuang Zhao,&nbsp;Zixi Jiang","doi":"10.1111/jebm.12586","DOIUrl":"10.1111/jebm.12586","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Plantar warts are common infectious cutaneous growths causing severe physiological and psychological discomforts in patients and heaving global financial burdens. However, paucity of clear-cut guidelines for plantar warts, selecting appropriate treatments for plantar warts remains challenging. The objective of the study is to evaluate the efficacy and safety of common treatments for plantar warts.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>PubMed, EMbase, and The Cochrane Library were searched from inception to March 1, 2023 for randomized controlled trials (RCTs) of plantar warts. The primary outcome (complete response) and secondary outcome (recurrence and pain) were extracted and combined using Bayesian network meta-analysis (NMA) with random-effect and fixed-effect models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Totally, 33 RCTs were included in the systematic review and quantitative NMA. In NMA of complete response, topical application of 1% cantharidin, 20% podophylotoxin, 30% salicylic acid (CPS), microneedles plus bleomycin (MNB), and intralesional bleomycin injection (INB) were the only three treatments significantly superior to no treatment (NT) and CPS was of the highest possibility to be the top-ranked treatment (SUCRA = 0.9363). However, traditional warts treatments, salicylic acid (SA) and cryotherapy were not superior to NT.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The NMA has produced evidence for using CPS, MNB, and INB, which are all topical antimitotic treatments, to improve the management of plantar warts. The classic treatment modalities for plantar warts, including SA and cryotherapy, may play a less important role in the clinical practice of plantar warts.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16090,"journal":{"name":"Journal of Evidence‐Based Medicine","volume":null,"pages":null},"PeriodicalIF":7.3,"publicationDate":"2024-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139502559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Core outcome sets for myocardial infarction in clinical trials of traditional Chinese medicine and Western medicine 中西医临床试验中心肌梗死的核心结果集。
IF 7.3 2区 医学 Q1 Medicine Pub Date : 2024-01-12 DOI: 10.1111/jebm.12579
Ruijin Qiu, Siqi Wan, Changming Zhong, Songjie Han, Tianmai He, Ya Huang, Xuxu Wei, Meng Li, Zhiyue Guan, Xinyi Zhang, Huanlin Wu, Hongcai Shang

Background

Clinical trials of traditional Chinese medicine (TCM) and Western medicine showed there was heterogeneity of outcome reporting in myocardial infarction (MI). Developing a core outcome set (COS) might improve the consistency of outcome reporting in future clinical trials.

Methods

A list of outcomes was developed based on a systematic review of randomized controlled trials (RCTs) of MI and semistructured interviews with MI patients. Two rounds of Delphi survey for clinicians, researchers, journal editors, and methodologists were conducted. An online questionnaire sent to nurses. After an online consensus meeting, a COS for MI RCTs was developed.

Results

After extracted data from clinical trials and discussed, 216 outcomes were included in round 1 of the Delphi survey. Seventy-four participants completed round 1 of the Delphi survey. Sixty-five participants completed round 2 of the Delphi survey. Twenty-two nurses completed the online questionnaire. Fifteen participants attended the online consensus meeting, and 14 of them voted and determined the final COS. For all types of MI, it was recommended that left ventricular ejection fraction and quality of life be measured and reported. For acute MI, the participants in the consensus meeting recommended the following core outcomes: death from cardio-cerebrovascular disease, cardiogenic shock, heart failure, troponin I, troponin T, creatine kinase isoenzyme, Killip class, target vessel revascularization, and emergency CABG. For previous MI, recurrent MI, recurrent angina pectoris, and heart failure readmission were recommended.

Conclusions

The COS for MI in RCTs provides recommendations for clinical trials that seek to improve outcomes for patients with MI.

背景:中西医临床试验显示,心肌梗死(MI)的结果报告存在异质性。制定核心结果集(COS)可提高未来临床试验结果报告的一致性:方法:根据对心肌梗死随机对照试验(RCT)的系统回顾和对心肌梗死患者的半结构式访谈,制定了一份结果列表。对临床医生、研究人员、期刊编辑和方法论专家进行了两轮德尔菲调查。向护士发送在线问卷。在线共识会议后,制定了 MI RCT 的 COS:从临床试验中提取数据并进行讨论后,216 项结果被纳入德尔菲调查的第一轮。74 位参与者完成了德尔菲调查的第一轮。65名参与者完成了德尔菲调查第二轮。22 名护士完成了在线问卷调查。15 名参与者参加了在线共识会议,其中 14 人进行了投票并确定了最终的 COS。对于所有类型的心肌梗死,建议测量并报告左心室射血分数和生活质量。对于急性心肌梗死,共识会议与会者推荐了以下核心结果:心脑血管疾病导致的死亡、心源性休克、心力衰竭、肌钙蛋白 I、肌钙蛋白 T、肌酸激酶同工酶、Killip 分级、靶血管再通术和急诊 CABG。对于既往的心肌梗死、复发性心肌梗死、复发性心绞痛和心力衰竭再入院,建议采用COS:RCT中的心肌梗死COS为旨在改善心肌梗死患者预后的临床试验提供了建议。
{"title":"Core outcome sets for myocardial infarction in clinical trials of traditional Chinese medicine and Western medicine","authors":"Ruijin Qiu,&nbsp;Siqi Wan,&nbsp;Changming Zhong,&nbsp;Songjie Han,&nbsp;Tianmai He,&nbsp;Ya Huang,&nbsp;Xuxu Wei,&nbsp;Meng Li,&nbsp;Zhiyue Guan,&nbsp;Xinyi Zhang,&nbsp;Huanlin Wu,&nbsp;Hongcai Shang","doi":"10.1111/jebm.12579","DOIUrl":"10.1111/jebm.12579","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Clinical trials of traditional Chinese medicine (TCM) and Western medicine showed there was heterogeneity of outcome reporting in myocardial infarction (MI). Developing a core outcome set (COS) might improve the consistency of outcome reporting in future clinical trials.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A list of outcomes was developed based on a systematic review of randomized controlled trials (RCTs) of MI and semistructured interviews with MI patients. Two rounds of Delphi survey for clinicians, researchers, journal editors, and methodologists were conducted. An online questionnaire sent to nurses. After an online consensus meeting, a COS for MI RCTs was developed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>After extracted data from clinical trials and discussed, 216 outcomes were included in round 1 of the Delphi survey. Seventy-four participants completed round 1 of the Delphi survey. Sixty-five participants completed round 2 of the Delphi survey. Twenty-two nurses completed the online questionnaire. Fifteen participants attended the online consensus meeting, and 14 of them voted and determined the final COS. For all types of MI, it was recommended that left ventricular ejection fraction and quality of life be measured and reported. For acute MI, the participants in the consensus meeting recommended the following core outcomes: death from cardio-cerebrovascular disease, cardiogenic shock, heart failure, troponin I, troponin T, creatine kinase isoenzyme, Killip class, target vessel revascularization, and emergency CABG. For previous MI, recurrent MI, recurrent angina pectoris, and heart failure readmission were recommended.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The COS for MI in RCTs provides recommendations for clinical trials that seek to improve outcomes for patients with MI.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16090,"journal":{"name":"Journal of Evidence‐Based Medicine","volume":null,"pages":null},"PeriodicalIF":7.3,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139424951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Risk prediction of hepatobiliary and pancreatic cancersin elderly Chinese: The Dongfeng-Tongji cohort 更正:中国老年人肝胆胰癌的风险预测:东风-同济队列。
IF 7.3 2区 医学 Q1 Medicine Pub Date : 2024-01-12 DOI: 10.1111/jebm.12580

Lyu J, Guan X, Zhou Y, Guo H, Cheng S, Wang C. Risk prediction of hepatobiliary and pancreatic cancers in elderly Chinese: The Dongfeng-Tongji cohort. J Evid Based Med. 2023; 16:39-49.

1. In Supplementary Figure l, the unit in “Diagnosis of pancreatic or hepatobiliary cancer in < 3 or > 70 weeks of follow-up” was incorrect. The unit “weeks” should be changed to “months.”

2. In the second last paragraph of the Results section, the text “and even lower for PC (0.21%, 95% CI (0.13%, 0.28%)) and PPV (67.63%, 95% CI (67.19%, 68.07%) specificity, Table 3)” should be modified to “and even lower for PC (0.21% (0.13-0.28%) PPV and 67.63% (67.19-68.07%) specificity, Table 3).”

3. In the second paragraph of the Discussion section, three numbers of AUC were incorrect. The number 0.828 on line 6 should be 0.818. The number 0.862 on line 12 should be 0.843. The number 0.890 on line 13 should be 0.873.

We apologize for these errors, which were introduced unintentionally during the revision (1 and 3) and the production process (2). The correction does not change any results and conclusions of the article.

Lyu J, Guan X, Zhou Y, Guo H, Cheng S, Wang C. 中国老年人肝胆胰癌的风险预测:东风-同济队列。J Evid Based Med.2023; 16:39-49.1.在补充图l中,"随访3周或70周诊断为胰腺癌或肝胆癌 "中的单位不正确。单位 "周 "应改为 "月"。结果部分倒数第二段中,"PC(0.21%,95% CI (0.13%, 0.28%))和 PPV(67.63%,95% CI (67.19%, 68.07%) 特异性,表 3)"应改为 "PC(0.21%,95% CI (0.13%, 0.28%))和 PPV(67.63%,95% CI (67.19%, 68.07%) 特异性,表 3)"。21% (0.13-0.28%) PPV 和 67.63% (67.19-68.07%) 特异性,表 3)"。 3.讨论部分第二段中,AUC 的三个数字不正确。第 6 行的数字 0.828 应为 0.818。第 12 行的数字 0.862 应为 0.843。第 13 行的数字 0.890 应为 0.873。我们对这些错误表示歉意,这些错误是在修订(1 和 3)和生产过程(2)中无意引入的。更正并不改变文章的任何结果和结论。
{"title":"Correction to: Risk prediction of hepatobiliary and pancreatic cancersin elderly Chinese: The Dongfeng-Tongji cohort","authors":"","doi":"10.1111/jebm.12580","DOIUrl":"10.1111/jebm.12580","url":null,"abstract":"<p>Lyu J, Guan X, Zhou Y, Guo H, Cheng S, Wang C. Risk prediction of hepatobiliary and pancreatic cancers in elderly Chinese: The Dongfeng-Tongji cohort. J Evid Based Med. 2023; 16:39-49.</p><p>1. In Supplementary Figure l, the unit in “Diagnosis of pancreatic or hepatobiliary cancer in &lt; 3 or &gt; 70 weeks of follow-up” was incorrect. The unit “weeks” should be changed to “months.”</p><p>2. In the second last paragraph of the Results section, the text “and even lower for PC (0.21%, 95% CI (0.13%, 0.28%)) and PPV (67.63%, 95% CI (67.19%, 68.07%) specificity, Table 3)” should be modified to “and even lower for PC (0.21% (0.13-0.28%) PPV and 67.63% (67.19-68.07%) specificity, Table 3).”</p><p>3. In the second paragraph of the Discussion section, three numbers of AUC were incorrect. The number 0.828 on line 6 should be 0.818. The number 0.862 on line 12 should be 0.843. The number 0.890 on line 13 should be 0.873.</p><p>We apologize for these errors, which were introduced unintentionally during the revision (1 and 3) and the production process (2). The correction does not change any results and conclusions of the article.</p>","PeriodicalId":16090,"journal":{"name":"Journal of Evidence‐Based Medicine","volume":null,"pages":null},"PeriodicalIF":7.3,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jebm.12580","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139466782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic performance of angiography-derived fractional flow reserve and CT-derived fractional flow reserve: A systematic review and Bayesian network meta-analysis 血管造影得出的分数血流储备和 CT 得出的分数血流储备的诊断性能:系统综述和贝叶斯网络荟萃分析。
IF 7.3 2区 医学 Q1 Medicine Pub Date : 2024-01-11 DOI: 10.1111/jebm.12573
Zhongxiu Chen, Junyan Zhang, Yujia Cai, Hongsen Zhao, Duolao Wang, Chen Li, Yong He

Objective

Accumulating evidence has demonstrated that fractional flow reserves (FFRs) derived from invasive coronary angiograms (CA-FFRs) and coronary computed tomography angiography-derived FFRs (CT-FFRs) are promising alternatives to wire-based FFRs. However, it remains unclear which method has better diagnostic performance. This systematic review and meta-analysis aimed to compare the diagnostic performances of the two approaches.

Methods

The Cochrane Library, PubMed, Embase, Medline (Ovid), the Chinese China National Knowledge Infrastructure Database (CNKI), VIP, and WanFang Data databases were searched for relevant studies that included comparisons between CA-FFR and CT-FFR, from their respective database inceptions until January 1, 2023. Studies where both noninvasive FFR (including CA-FFR and CT-FFR) and invasive FFR (as a reference standard) were performed for the diagnosis of ischemic coronary artery disease and were designed as prospective, paired diagnostic studies, were pulled. The diagnostic test accuracy method and Bayesian hierarchical summary receiver operating characteristic (ROC) model for network meta-analysis (NMA) of diagnostic tests (HSROC-NMADT) were both used to perform a meta-analysis on the data.

Results

Twenty-six studies were included in this NMA. The results from both the diagnostic test accuracy and HSROC-NMADT methods revealed that the diagnostic accuracy of CA-FFR was higher than that of CT-FFR, in terms of sensitivity (Se; 0.86 vs. 0.84), specificity (Sp; 0.90 vs. 0.78), positive predictive value (PPV; 0.83 vs. 0.70), and negative predictive value (NPV; 0.91 vs. 0.89) for the detection of myocardial ischemia. A cumulative ranking curve analysis indicated that CA-FFR had a higher diagnostic accuracy than CT-FFR in the context of this study, with a higher area under the ROC curve (AUC; 0.94 vs. 0.87).

Conclusions

Although both of these two commonly used virtual FFR methods showed high levels of diagnostic accuracy, we demonstrated that CA-FFR had a better Se, Sp, PPV, NPV, and AUC than CT-FFR. However, this study provided only indirect comparisions; therefore, larger studies are warranted to directly compare the diagnostic performances of these two approaches.

目的:越来越多的证据表明,由有创冠状动脉造影(CA-FFR)和冠状动脉计算机断层扫描血管造影(CT-FFR)得出的分数血流储备(FFR)很有希望替代基于导线的 FFR。然而,目前仍不清楚哪种方法具有更好的诊断性能。本系统综述和荟萃分析旨在比较这两种方法的诊断性能:方法:在 Cochrane Library、PubMed、Embase、Medline (Ovid)、中国国家知识基础设施数据库 (CNKI)、VIP 和万方数据等数据库中检索了自各自数据库建立至 2023 年 1 月 1 日期间纳入 CA-FFR 和 CT-FFR 比较的相关研究。在这些研究中,无创 FFR(包括 CA-FFR 和 CT-FFR)和有创 FFR(作为参考标准)均用于缺血性冠状动脉疾病的诊断,且均为前瞻性、配对诊断研究。采用诊断测试准确性方法和贝叶斯分层汇总接收器操作特征(ROC)模型对数据进行诊断测试网络荟萃分析(NMA)(HSROC-NMADT):本次 NMA 共纳入了 26 项研究。诊断测试准确性和 HSROC-NMADT 两种方法的结果显示,在检测心肌缺血方面,CA-FFR 的诊断准确性在灵敏度(Se;0.86 对 0.84)、特异性(Sp;0.90 对 0.78)、阳性预测值(PPV;0.83 对 0.70)和阴性预测值(NPV;0.91 对 0.89)方面均高于 CT-FFR。累积排名曲线分析表明,在本研究中,CA-FFR 的诊断准确率高于 CT-FFR,ROC 曲线下面积(AUC;0.94 对 0.87)更高:尽管这两种常用的虚拟 FFR 方法都显示出较高的诊断准确性,但我们发现 CA-FFR 的 Se、Sp、PPV、NPV 和 AUC 均优于 CT-FFR。不过,本研究仅提供了间接比较;因此,需要进行更大规模的研究,以直接比较这两种方法的诊断性能。
{"title":"Diagnostic performance of angiography-derived fractional flow reserve and CT-derived fractional flow reserve: A systematic review and Bayesian network meta-analysis","authors":"Zhongxiu Chen,&nbsp;Junyan Zhang,&nbsp;Yujia Cai,&nbsp;Hongsen Zhao,&nbsp;Duolao Wang,&nbsp;Chen Li,&nbsp;Yong He","doi":"10.1111/jebm.12573","DOIUrl":"10.1111/jebm.12573","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Accumulating evidence has demonstrated that fractional flow reserves (FFRs) derived from invasive coronary angiograms (CA-FFRs) and coronary computed tomography angiography-derived FFRs (CT-FFRs) are promising alternatives to wire-based FFRs. However, it remains unclear which method has better diagnostic performance. This systematic review and meta-analysis aimed to compare the diagnostic performances of the two approaches.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The Cochrane Library, PubMed, Embase, Medline (Ovid), the Chinese China National Knowledge Infrastructure Database (CNKI), VIP, and WanFang Data databases were searched for relevant studies that included comparisons between CA-FFR and CT-FFR, from their respective database inceptions until January 1, 2023. Studies where both noninvasive FFR (including CA-FFR and CT-FFR) and invasive FFR (as a reference standard) were performed for the diagnosis of ischemic coronary artery disease and were designed as prospective, paired diagnostic studies, were pulled. The diagnostic test accuracy method and Bayesian hierarchical summary receiver operating characteristic (ROC) model for network meta-analysis (NMA) of diagnostic tests (HSROC-NMADT) were both used to perform a meta-analysis on the data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twenty-six studies were included in this NMA. The results from both the diagnostic test accuracy and HSROC-NMADT methods revealed that the diagnostic accuracy of CA-FFR was higher than that of CT-FFR, in terms of sensitivity (Se; 0.86 vs. 0.84), specificity (Sp; 0.90 vs. 0.78), positive predictive value (PPV; 0.83 vs. 0.70), and negative predictive value (NPV; 0.91 vs. 0.89) for the detection of myocardial ischemia. A cumulative ranking curve analysis indicated that CA-FFR had a higher diagnostic accuracy than CT-FFR in the context of this study, with a higher area under the ROC curve (AUC; 0.94 vs. 0.87).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Although both of these two commonly used virtual FFR methods showed high levels of diagnostic accuracy, we demonstrated that CA-FFR had a better Se, Sp, PPV, NPV, and AUC than CT-FFR. However, this study provided only indirect comparisions; therefore, larger studies are warranted to directly compare the diagnostic performances of these two approaches.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16090,"journal":{"name":"Journal of Evidence‐Based Medicine","volume":null,"pages":null},"PeriodicalIF":7.3,"publicationDate":"2024-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139417297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reporting, handling, and interpretation of time-varying drug treatments in observational studies using routinely collected healthcare data 利用日常收集的医疗保健数据,在观察性研究中报告、处理和解释随时间变化的药物治疗方法
IF 7.3 2区 医学 Q1 Medicine Pub Date : 2023-12-18 DOI: 10.1111/jebm.12577
Wen Wang, Qiao He, Jiayue Xu, Mei Liu, Mingqi Wang, Qianrui Li, Xia Zhang, Yunxiang Huang, Yuanjin Zhang, Ling Li, Kang Zou, Guowei Li, Kevin Lu, Pei Gao, Feng Chen, Jeff Jianfei Guo, Min Yang, Xin Sun
Time-varying drug treatments are common in studies using routinely collected health data (RCD) for assessing treatment effects. This study aimed to examine how these studies reported, handled, and interpreted time-varying drug treatments.
在使用常规收集的健康数据(RCD)评估治疗效果的研究中,时变药物治疗很常见。本研究旨在探讨这些研究如何报告、处理和解释时变药物治疗。
{"title":"Reporting, handling, and interpretation of time-varying drug treatments in observational studies using routinely collected healthcare data","authors":"Wen Wang, Qiao He, Jiayue Xu, Mei Liu, Mingqi Wang, Qianrui Li, Xia Zhang, Yunxiang Huang, Yuanjin Zhang, Ling Li, Kang Zou, Guowei Li, Kevin Lu, Pei Gao, Feng Chen, Jeff Jianfei Guo, Min Yang, Xin Sun","doi":"10.1111/jebm.12577","DOIUrl":"https://doi.org/10.1111/jebm.12577","url":null,"abstract":"Time-varying drug treatments are common in studies using routinely collected health data (RCD) for assessing treatment effects. This study aimed to examine how these studies reported, handled, and interpreted time-varying drug treatments.","PeriodicalId":16090,"journal":{"name":"Journal of Evidence‐Based Medicine","volume":null,"pages":null},"PeriodicalIF":7.3,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138717267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Causal relationship between sleep traits and cognitive impairment: A Mendelian randomization study 睡眠特征与认知障碍之间的因果关系:孟德尔随机研究
IF 7.3 2区 医学 Q1 Medicine Pub Date : 2023-12-18 DOI: 10.1111/jebm.12576
Qing Wang, Shihan Xu, Fenglan Liu, Yanfei Liu, Keji Chen, Luqi Huang, Fengqin Xu, Yue Liu
Observational studies had demonstrated a link between sleep disturbances and cognitive decline. Here, we aimed to investigate the causal association between genetically predicted sleep traits and cognitive impairment using Mendelian randomization (MR).
观察性研究表明,睡眠障碍与认知能力下降之间存在联系。在此,我们旨在利用孟德尔随机法(MR)研究基因预测的睡眠特征与认知障碍之间的因果关系。
{"title":"Causal relationship between sleep traits and cognitive impairment: A Mendelian randomization study","authors":"Qing Wang, Shihan Xu, Fenglan Liu, Yanfei Liu, Keji Chen, Luqi Huang, Fengqin Xu, Yue Liu","doi":"10.1111/jebm.12576","DOIUrl":"https://doi.org/10.1111/jebm.12576","url":null,"abstract":"Observational studies had demonstrated a link between sleep disturbances and cognitive decline. Here, we aimed to investigate the causal association between genetically predicted sleep traits and cognitive impairment using Mendelian randomization (MR).","PeriodicalId":16090,"journal":{"name":"Journal of Evidence‐Based Medicine","volume":null,"pages":null},"PeriodicalIF":7.3,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138717264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of pharmacological intervention for smoking cessation in smokers with diseases: A systematic review and network meta-analysis 药物干预对疾病吸烟者戒烟的有效性和安全性:系统综述和网络荟萃分析
IF 7.3 2区 医学 Q1 Medicine Pub Date : 2023-12-16 DOI: 10.1111/jebm.12570
Xin Xing, Xue Shang, Xinxin Deng, Kangle Guo, E Fenfen, Liying Zhou, Yongsheng Wang, Chaoqun Yang, Kehu Yang, Xiuxia Li
To investigate the most effective and best-tolerated drugs for treating diseased smokers.
研究治疗患病吸烟者的最有效、最耐受的药物。
{"title":"Efficacy and safety of pharmacological intervention for smoking cessation in smokers with diseases: A systematic review and network meta-analysis","authors":"Xin Xing, Xue Shang, Xinxin Deng, Kangle Guo, E Fenfen, Liying Zhou, Yongsheng Wang, Chaoqun Yang, Kehu Yang, Xiuxia Li","doi":"10.1111/jebm.12570","DOIUrl":"https://doi.org/10.1111/jebm.12570","url":null,"abstract":"To investigate the most effective and best-tolerated drugs for treating diseased smokers.","PeriodicalId":16090,"journal":{"name":"Journal of Evidence‐Based Medicine","volume":null,"pages":null},"PeriodicalIF":7.3,"publicationDate":"2023-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138717263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First-line CDK4/6 inhibitor-based combinations for HR+/HER2– advanced breast cancer: A Bayesian network meta-analysis 基于CDK4/6抑制剂的一线联合用药治疗HR+/HER2-晚期乳腺癌:贝叶斯网络荟萃分析
IF 7.3 2区 医学 Q1 Medicine Pub Date : 2023-12-16 DOI: 10.1111/jebm.12571
Xianan Guo, Yunxiang Zhou, Kun Zhang, Wei Lu, Xi Zhong, Shijie Wu, Lu Shen, Huihui Chen, Yiding Chen

Background

International guidelines recommend cyclin-dependent kinase 4/6 inhibitor (CDK4/6i)-based first-line therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC). However, direct drug comparisons are lacking. We aimed to identify the most effective and safe therapy through network meta-analysis (NMA).

Methods

We searched PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials, and OpenGrey up to September 30, 2023. Eligible studies included randomized controlled trials (RCTs) assessing endocrine therapy alone or in combination with CDK4/6i as first-line endocrine treatment for HR+/HER2− ABC patients. The hazard ratios for progression-free survival (PFS) and overall survival (OS) and relative risks for objective response rate and adverse events (AEs) were available in selected trials. We performed a Bayesian NMA following PRISMA guidelines.

Results

Thirteen RCTs, involving 10 treatments, were included. Most studies were at low risk of bias. Regarding PFS, ribociclib+fulvestrant ranked first with a surface under the cumulative ranking curve (SUCRA) of 85.0%, followed by dalpiciclib+nonsteroidal aromatase inhibitor (NSAI) (SUCRA = 78.9%). Considering OS, the top three ranked treatments were ribociclib+fulvestrant (SUCRA = 94.1%), abemaciclib+NSAI (SUCRA = 69.9%), and ribociclib+NSAI (SUCRA = 68.5%). Out of four CDK4/6is, ribociclib minimized the grade 3/4 AEs, while dalpiciclib demonstrated the worst safety. Publication bias could not be ignored in our analyses, and the certainty of evidence was downgraded primarily due to imprecision.

Conclusions

Ribociclib+fulvestrant probably represents the best option in a first-line setting. When combined with NSAI, dalpiciclib likely showed the best efficacy but the worst safety. Abemaciclib+NSAI and ribociclib+NSAI could also be promising treatments, while palbociclib presented inferiority. (PROSPERO Registration No. CRD42022370271)

背景:国际指南推荐对激素受体阳性、人表皮生长因子受体2阴性(HR+/HER2-)的晚期乳腺癌(ABC)进行基于细胞周期蛋白依赖性激酶4/6抑制剂(CDK4/6i)的一线治疗。然而,目前还缺乏直接的药物比较。我们旨在通过网络荟萃分析(NMA)找出最有效、最安全的疗法:我们检索了截至 2023 年 9 月 30 日的 PubMed、Embase、Web of Science、Cochrane Central Register of Controlled Trials 和 OpenGrey。符合条件的研究包括随机对照试验(RCT),这些试验评估了内分泌治疗单独或与CDK4/6i联用作为HR+/HER2-ABC患者一线内分泌治疗的情况。部分试验提供了无进展生存期(PFS)和总生存期(OS)的危险比以及客观反应率和不良事件(AEs)的相对风险。我们按照 PRISMA 指南进行了贝叶斯 NMA:结果:共纳入 13 项 RCT,涉及 10 种治疗方法。大多数研究的偏倚风险较低。在PFS方面,ribociclib+氟维司群排名第一,累积排名曲线下表面值(SUCRA)为85.0%,其次是dalpiciclib+非甾体芳香化酶抑制剂(NSAI)(SUCRA = 78.9%)。考虑到OS,排名前三的治疗方法分别是ribociclib+氟维司群(SUCRA=94.1%)、abemaciclib+NSAI(SUCRA=69.9%)和ribociclib+NSAI(SUCRA=68.5%)。在四种CDK4/6is中,ribociclib将3/4级AE降至最低,而dalpiciclib的安全性最差。我们的分析不能忽视发表偏倚,证据的确定性主要由于不精确而被降级:结论:Ribociclib+氟维司群可能是一线治疗的最佳选择。结论:Ribociclib+氟维司群可能是一线治疗中的最佳选择。当与非甾体抗炎药物(NSAI)联合使用时,dalpiciclib的疗效可能最好,但安全性最差。Abemaciclib+NSAI和ribociclib+NSAI也是很有前景的治疗方法,而palbociclib则表现较差。(PROSPERO 注册号:CRD42022370271)。
{"title":"First-line CDK4/6 inhibitor-based combinations for HR+/HER2– advanced breast cancer: A Bayesian network meta-analysis","authors":"Xianan Guo,&nbsp;Yunxiang Zhou,&nbsp;Kun Zhang,&nbsp;Wei Lu,&nbsp;Xi Zhong,&nbsp;Shijie Wu,&nbsp;Lu Shen,&nbsp;Huihui Chen,&nbsp;Yiding Chen","doi":"10.1111/jebm.12571","DOIUrl":"10.1111/jebm.12571","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>International guidelines recommend cyclin-dependent kinase 4/6 inhibitor (CDK4/6i)-based first-line therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC). However, direct drug comparisons are lacking. We aimed to identify the most effective and safe therapy through network meta-analysis (NMA).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We searched PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials, and OpenGrey up to September 30, 2023. Eligible studies included randomized controlled trials (RCTs) assessing endocrine therapy alone or in combination with CDK4/6i as first-line endocrine treatment for HR+/HER2− ABC patients. The hazard ratios for progression-free survival (PFS) and overall survival (OS) and relative risks for objective response rate and adverse events (AEs) were available in selected trials. We performed a Bayesian NMA following PRISMA guidelines.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Thirteen RCTs, involving 10 treatments, were included. Most studies were at low risk of bias. Regarding PFS, ribociclib+fulvestrant ranked first with a surface under the cumulative ranking curve (SUCRA) of 85.0%, followed by dalpiciclib+nonsteroidal aromatase inhibitor (NSAI) (SUCRA = 78.9%). Considering OS, the top three ranked treatments were ribociclib+fulvestrant (SUCRA = 94.1%), abemaciclib+NSAI (SUCRA = 69.9%), and ribociclib+NSAI (SUCRA = 68.5%). Out of four CDK4/6is, ribociclib minimized the grade 3/4 AEs, while dalpiciclib demonstrated the worst safety. Publication bias could not be ignored in our analyses, and the certainty of evidence was downgraded primarily due to imprecision.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Ribociclib+fulvestrant probably represents the best option in a first-line setting. When combined with NSAI, dalpiciclib likely showed the best efficacy but the worst safety. Abemaciclib+NSAI and ribociclib+NSAI could also be promising treatments, while palbociclib presented inferiority. (PROSPERO Registration No. CRD42022370271)</p>\u0000 </section>\u0000 </div>","PeriodicalId":16090,"journal":{"name":"Journal of Evidence‐Based Medicine","volume":null,"pages":null},"PeriodicalIF":7.3,"publicationDate":"2023-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138806311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of scalp stimulation for multidomain cognitive impairment in patients with post-stroke cognitive impairment and dementia: A network meta-analysis and meta-regression of moderators 头皮刺激对脑卒中后认知障碍和痴呆患者多域认知障碍的疗效:网络荟萃分析和调节因子的荟萃回归
IF 7.3 2区 医学 Q1 Medicine Pub Date : 2023-12-15 DOI: 10.1111/jebm.12568
Minjie Xu, Ying Li, Chi Zhang, Yanan Ma, Leyi Zhang, Yuai Yang, Zihan Zhang, Tiantian Meng, Junyi He, Haifang Wang, Shuren Li, Georg S Kranz, Mingjing Zhao, Jingling Chang
Scalp stimulation has gained more traction for post-stroke cognitive impairment and dementia (PSCID); the interaction between stimulation targets and parameters influences the response to the stimulation. However, the most efficacious treatment for improving different domains of cognitive impairment remains unknown.
头皮刺激疗法在治疗脑卒中后认知障碍和痴呆症(PSCID)方面获得了越来越多的关注;刺激目标和参数之间的相互作用影响着对刺激的反应。然而,改善认知障碍不同领域的最有效治疗方法仍是未知数。
{"title":"Efficacy of scalp stimulation for multidomain cognitive impairment in patients with post-stroke cognitive impairment and dementia: A network meta-analysis and meta-regression of moderators","authors":"Minjie Xu, Ying Li, Chi Zhang, Yanan Ma, Leyi Zhang, Yuai Yang, Zihan Zhang, Tiantian Meng, Junyi He, Haifang Wang, Shuren Li, Georg S Kranz, Mingjing Zhao, Jingling Chang","doi":"10.1111/jebm.12568","DOIUrl":"https://doi.org/10.1111/jebm.12568","url":null,"abstract":"Scalp stimulation has gained more traction for post-stroke cognitive impairment and dementia (PSCID); the interaction between stimulation targets and parameters influences the response to the stimulation. However, the most efficacious treatment for improving different domains of cognitive impairment remains unknown.","PeriodicalId":16090,"journal":{"name":"Journal of Evidence‐Based Medicine","volume":null,"pages":null},"PeriodicalIF":7.3,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138717266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Scope, design, and reporting of prediction models for antineoplastic drugs-related adverse drug events: A systematic review of machine learning and traditional modeling. 抗肿瘤药物相关不良药物事件预测模型的范围、设计和报告:机器学习和传统建模的系统综述。
IF 7.3 2区 医学 Q1 Medicine Pub Date : 2023-12-01 Epub Date: 2023-10-20 DOI: 10.1111/jebm.12558
Dan Jiang, Zaiwei Song, Yang Hu, Xinya Li, Rongsheng Zhao
{"title":"Scope, design, and reporting of prediction models for antineoplastic drugs-related adverse drug events: A systematic review of machine learning and traditional modeling.","authors":"Dan Jiang, Zaiwei Song, Yang Hu, Xinya Li, Rongsheng Zhao","doi":"10.1111/jebm.12558","DOIUrl":"10.1111/jebm.12558","url":null,"abstract":"","PeriodicalId":16090,"journal":{"name":"Journal of Evidence‐Based Medicine","volume":null,"pages":null},"PeriodicalIF":7.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49678343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Evidence‐Based Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1